Efficacy and Tolerability of Solifenacin 5 Mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2017 Jan 4

PMID 28049246

Citations 5

Authors

Sang Don Lee

Jae Min Chung

Dong Il Kang

Dong Soo Ryu

Won Yeol Cho

Sungchan Park

Affiliations

Soon will be listed here.

Abstract

We investigated the efficacy and tolerability of solifenacin 5 mg fixed dose in children with newly diagnosed idiopathic overactive bladder (OAB). A total of 34 children (male/female patients = 16/18) aged under 13 years (mean age: 7.2 ± 2.3; range: 5-12) who were newly diagnosed with OAB from January 2012 to September 2014 were prospectively evaluated with open-label protocol. All patients were treated with solifenacin 5 mg fixed dose once daily for at least 4 weeks. The efficacy and tolerability of solifenacin were evaluated 4, 8, and 12 weeks after the initiation of treatment. The mean voiding frequency during daytime was decreased from 9.4 ± 3.0 to 6.5 ± 2.3 times after the 12-week treatment (P < 0.001). The mean total OAB symptom score (OABSS) decreased from 7.7 ± 4.2 to 3.1 ± 3.1 after the 12-week treatment (P < 0.001). The urgency and urgency urinary incontinence (UUI) domains significantly improved from the 12-week treatment, and complete resolution of urgency occurred in 38.9% of patients and the percentage of children with UUI among urgent patients decreased from 79.4% to 57.1%. According to 3-day voiding diaries, the average bladder capacity increased from 90.4 ± 44.4 to 156.2 ± 67.3 mL (P < 0.001). Drug-induced adverse effects (AEs) were reported in 7 patients (20.6%). Our results indicate that solifenacin 5 mg fixed dose is effective against OAB symptoms, and its tolerability is acceptable without significant AEs in children with OAB.

Citing Articles

Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder.

Hu Y, Zhang H BMC Urol. 2024; 24(1):97.

PMID: 38664686 PMC: 11044419. DOI: 10.1186/s12894-024-01486-9.

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.

Kim S, Park M, Chae C, Yoon J, Kwon T, Park S Investig Clin Urol. 2021; 62(3):317-323.

PMID: 33834641 PMC: 8100008. DOI: 10.4111/icu.20200380.

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity.

Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F Pharmacol Res Perspect. 2020; 8(6):e00684.

PMID: 33231929 PMC: 7685239. DOI: 10.1002/prp2.684.

Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study.

Shim M, Kim J, Bang W, Lee Y, Cho S, Cho J Investig Clin Urol. 2020; 61(6):600-606.

PMID: 32985146 PMC: 7606123. DOI: 10.4111/icu.20200053.

Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis.

Noh J, Lee B, Kim J Int Urol Nephrol. 2019; 51(9):1459-1471.

PMID: 31243632 DOI: 10.1007/s11255-019-02209-y.

References

Cardozo L, Thorpe A, Warner J, Sidhu M . The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010; 106(4):506-14. DOI: 10.1111/j.1464-410X.2009.09160.x. View

Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E . Solifenacin for therapy resistant overactive bladder. J Urol. 2009; 182(4 Suppl):2040-4. DOI: 10.1016/j.juro.2009.05.100. View

Kim S, Kim K, Kim Y, Kim J, Moon D, Park S . Evaluation of maximum voided volume in Korean children by use of a 48-h frequency volume chart. BJU Int. 2011; 110(4):597-600. DOI: 10.1111/j.1464-410X.2011.10799.x. View

McKeage K . Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig. 2013; 33(1):71-91. DOI: 10.1007/s40261-012-0046-9. View

Jeong S, Homma Y, Oh S . Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. Qual Life Res. 2013; 23(1):285-92. DOI: 10.1007/s11136-013-0440-7. View

Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M . Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010; 184(4 Suppl):1668-73. DOI: 10.1016/j.juro.2010.03.124. View

Chapple C, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M . Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93(3):303-10. DOI: 10.1111/j.1464-410x.2004.04606.x. View

Chapple C, Arano P, Bosch J, De Ridder D, Kramer A, Ridder A . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2003; 93(1):71-7. DOI: 10.1111/j.1464-410x.2004.04561.x. View

Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillen U . Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol. 2008; 55(3):729-36. DOI: 10.1016/j.eururo.2008.04.062. View

10.

Maman K, Aballea S, Nazir J, Desroziers K, Neine M, Siddiqui E . Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2013; 65(4):755-65. DOI: 10.1016/j.eururo.2013.11.010. View

11.

Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z . An adverse event capture and management system for cancer studies. BMC Bioinformatics. 2015; 16 Suppl 13:S6. PMC: 4597098. DOI: 10.1186/1471-2105-16-S13-S6. View

12.

Park S, Pai K, Kim J, Park K, Kim K, Song S . Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study. J Korean Med Sci. 2014; 29(11):1550-4. PMC: 4234924. DOI: 10.3346/jkms.2014.29.11.1550. View

13.

Malhotra B, El-Tahtawy A, Wang E, Darekar A, Cossons N, Crook T . Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. J Pediatr Urol. 2012; 8(4):336-42. DOI: 10.1016/j.jpurol.2012.02.008. View

14.

Chung J, Lee S, Kang D, Kwon D, Kim K, Kim S . Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study. Urology. 2008; 73(1):63-7. DOI: 10.1016/j.urology.2008.06.063. View

15.

Schulte-Baukloh H, Murtz G, Heine G, Austin P, Miller K, Michael T . Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2011; 8(4):386-92. DOI: 10.1016/j.jpurol.2011.07.014. View

16.

Schroder A, Thuroff J . New strategies for medical management of overactive bladder in children. Curr Opin Urol. 2011; 20(4):313-7. DOI: 10.1097/MOU.0b013e32833aa185. View

17.

Wada Y, Yoshida M, Kitani K, Kikukawa H, Ichinose A, Takahashi W . Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther. 1995; 330(1):76-89. View

18.

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O . Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015; 116(4):612-22. DOI: 10.1111/bju.13068. View

19.

Nitti V, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo J . Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013; 67(7):619-32. PMC: 3752932. DOI: 10.1111/ijcp.12194. View

20.

Alloussi S, Murtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E . Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. BJU Int. 2009; 106(4):550-6. DOI: 10.1111/j.1464-410X.2009.09129.x. View